Immediate release oxycodone

Immediate release oxycodone



Roxicodone (Oxycodone Hydrochloride) Drug Information

9/13/2016
02:03 | Olivia Holiday
Immediate release oxycodone
Roxicodone (Oxycodone Hydrochloride) Drug Information

ROXICODONE (oxycodone hydrochloride) tablets are an immediate-release oral formulation of oxycodone hydrochloride indicated for the management of.

In converting patients from other opioids to ROXICODONE (oxycodone hydrochloride) close observation and adjustment of dosage based upon the patient's response to ROXICODONE (oxycodone hydrochloride) is imperative.

Egalet Corporation Our Products

11/15/2016
04:23 | Olivia Holiday
Immediate release oxycodone
Egalet Corporation Our Products

OXAYDO is the first and only approved immediate-release oxycodone product designed to deter abuse, indicated for the management of acute and chronic.

Find out more about opportunities with Egalet. Career Contact.

OXAYDO is the first and only approved immediate-release oxycodone product designed to deter abuse, indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. Read More.

Respiratory depression is the primary risk of OXAYDO and it must be used with extreme caution in patients with chronic obstructive pulmonary disease or cor pulmonale, in patients with decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression.

Investor Contact Media Contact EGALET U.S.

Safety and Tolerability of Biphasic ImmediateReleaseExtended

10/14/2016
03:13 | Ethan Adamson
Immediate release oxycodone
Safety and Tolerability of Biphasic ImmediateReleaseExtended

Safety and Tolerability of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets: Analysis of 11 Clinical Trials.

Adverse events (AEs) experienced by ≥ 10% of participants receiving IR/ER OC/APAP in all trials were pruritus, nausea, vomiting, dizziness, headache, and somnolence; these AEs occurred with similar frequency for equianalgesic doses of IR OC/APAP and IR OC but less frequently for IR tramadol HCl/APAP. In the HAP study, crushing IR/ER or IR OC/APAP tablets did not increase frequency of AEs. No serious (SAE) or severe AEs were reported in phase 1 trials. Constipation was experienced by < 10% of participants receiving IR/ER OC/APAP.

Immediate-Release Oxycodone Capsules Study in Cancer Pain

4/8/2016
03:47 | Matthew Adderiy
Immediate release oxycodone
Immediate-Release Oxycodone Capsules Study in Cancer Pain

Official Title: A Comparative Study of Immediate-Release Oxycodone Capsules Versus Immediate-Release Morphine Tablets for the Treatment.

Oxycodone OXAYDO

3/7/2016
04:57 | Madison Holmes
Immediate release oxycodone
Oxycodone OXAYDO

Egalet Announces Commercial Launch of OXAYDO, the First and Only Immediate-Release Oxycodone Designed to Discourage Intranasal.